Topic Archives: Johnson and Johnson (JNJ)

“Rising Healthcare Demand Enables 100+ Year Dividend-Paying Pharma Giant to Enter Best Dividend Stocks List”

Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]

The Manchurian Candida

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and biography here.] “Many things you hear in this room are untrue.” (sign posted in Yale-New Haven Medical Center physician cafeteria) […]

The Second Coming of TransEnterix?

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see all of his previous articles and most recent comments here.] Go on, admit it: you enjoyed that rambunctious little scene in Ridley Scott’s Prometheus […]

The Long Case for Receptos

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]

Payola from Portola?

In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]

“Triple-Digit Profits from the Diabetic ‘Patch’ Company Going to $1 Billion.”

Today the pitch that’s been catching my eye is from Mitchell Clark for his Biotech Breakthrough Stock Report — we haven’t covered this newsletter before, but we have certainly covered teaser spiels from Mitchell Clark’s wide variety of Lombardi-published newsletters in the past (before he was a biotech expert this week, he was a bible […]

Hepatitis with a C

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Comments

  • Travis Johnson, Stock Gumshoe

    I expect they'll survive their legal problems just fine (Talc and Opioids), but I'd rather see some pessimism from inves...

  • Avatar

    Travis ---you're right on-----The five he talks about are: ABBV, PFE, JNJ, MRK amd UNH...

  • Avatar

    Hi Todd This should pick up a lot of momentum. Heck Norchi has been thinking of this commercialization moment si...

  • Avatar

    http://www.investor.jnj.com/janssen-phase-3-study-programme-of-esketamine-nasal-spray-in-patients-with-treatment-resista...

  • Avatar

    http://www.investor.jnj.com/janssen-phase-3-study-programme-of-esketamine-nasal-spray-in-patients-with-treatment-resista...

  • Avatar

    http://www.businessinsider.com/depression-medication-treatment-ketamine-2018-5 Not sure where you got the tease, but ...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch